当前位置: 首页 >> 检索结果
321. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.
作者: Yuliya Lytvyn.;Karen Kimura.;Nuala Peter.;Vesta Lai.;Josephine Tse.;Leslie Cham.;Bruce A Perkins.;Nima Soleymanlou.;David Z I Cherney.
来源: Circulation. 2022年146卷6期450-462页
The cardiorenal effects of sodium-glucose cotransporter 2 inhibition (empagliflozin 25 mg QD) combined with angiotensin-converting enzyme inhibition (ramipril 10 mg QD) were assessed in this mechanistic study in patients with type 1 diabetes with potential renal hyperfiltration.
322. Effects of Cuisine-Based Chinese Heart-Healthy Diet in Lowering Blood Pressure Among Adults in China: Multicenter, Single-Blind, Randomized, Parallel Controlled Feeding Trial.
作者: Yanfang Wang.;Lin Feng.;Guo Zeng.;Huilian Zhu.;Jianqin Sun.;Pei Gao.;Jihong Yuan.;Xi Lan.;Shuyi Li.;Yanfang Zhao.;Xiayan Chen.;Hongli Dong.;Si Chen.;Zhen Li.;Yidan Zhu.;Ming Li.;Xiang Li.;Zhenquan Yang.;Huijuan Li.;Hai Fang.;Gaoqiang Xie.;Pao-Hwa Lin.;Junshi Chen.;Yangfeng Wu.; .
来源: Circulation. 2022年146卷4期303-315页
More than one-fifth of the world's population consumes Chinese cuisines regularly, but no evidence-based healthy diets fitting the Chinese food culture are available for implementation.
323. Community-Based, Cluster-Randomized Pilot Trial of a Cardiovascular Mobile Health Intervention: Preliminary Findings of the FAITH! Trial.
作者: LaPrincess C Brewer.;Sarah Jenkins.;Sharonne N Hayes.;Ashok Kumbamu.;Clarence Jones.;Lora E Burke.;Lisa A Cooper.;Christi A Patten.
来源: Circulation. 2022年146卷3期175-190页
African Americans continue to have suboptimal cardiovascular health (CVH) based on the American Heart Association Life's Simple 7 (LS7), 7 health-promoting behaviors and biological risk factors (eg, physical activity, blood pressure). Innovative, community-level interventions in partnership with trusted institutions such as African American churches are potential means to improve CVH in this population.
324. Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial.
作者: Douglas L Packer.;David J Wilber.;Suraj Kapa.;Katia Dyrda.;Isabelle Nault.;Ammar M Killu.;Arvindh Kanagasundram.;Travis Richardson.;William Stevenson.;Atul Verma.;Michael Curley.; .
来源: Circ Arrhythm Electrophysiol. 2022年15卷8期e010347页
Ablation of ventricular tachycardia (VT) is limited by the inability to create penetrating lesions to reach intramyocardial origins. Intramural needle ablation using in-catheter, heated saline-enhanced radio frequency (SERF) energy uses convective heating to increase heat transfer and produce deeper, controllable lesions at intramural targets. This first-in-human trial was designed to evaluate the safety and efficacy of SERF needle ablation in patients with refractory VT.
325. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
作者: Emil Hagström.;P Gabriel Steg.;Michael Szarek.;Deepak L Bhatt.;Vera A Bittner.;Nicolas Danchin.;Rafael Diaz.;Shaun G Goodman.;Robert A Harrington.;J Wouter Jukema.;Evangelos Liberopoulos.;Nikolaus Marx.;Jennifer McGinniss.;Garen Manvelian.;Robert Pordy.;Michel Scemama.;Harvey D White.;Andreas M Zeiher.;Gregory G Schwartz.; .
来源: Circulation. 2022年146卷9期657-672页
Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain.
326. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
作者: P Christian Schulze.;Jürgen Bogoviku.;Julian Westphal.;Pawel Aftanski.;Franz Haertel.;Sissy Grund.;Stephan von Haehling.;Ulrike Schumacher.;Sven Möbius-Winkler.;Martin Busch.
来源: Circulation. 2022年146卷4期289-298页
Effective diuretic regimens using loop diuretics in patients with acute decompensated heart failure are often limited by the development of worsening kidney function. Sodium-glucose cotransporter-2 inhibitors induce glucosuria and sodium excretion with nephroprotective effects in patients with stable heart failure but their role in acute decompensated heart failure is unclear.
327. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
作者: Gerasimos Filippatos.;Javed Butler.;Dimitrios Farmakis.;Faiez Zannad.;Anne Pernille Ofstad.;João Pedro Ferreira.;Jennifer B Green.;Julio Rosenstock.;Sven Schnaidt.;Martina Brueckmann.;Stuart J Pocock.;Milton Packer.;Stefan D Anker.; .
来源: Circulation. 2022年146卷9期676-686页
Empagliflozin improves outcomes in patients with heart failure with a preserved ejection fraction, but whether the effects are consistent in patients with and without diabetes remains to be elucidated.
328. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
作者: Paul M Ridker.;Nader Rifai.;Jean MacFadyen.;Robert J Glynn.;Lixia Jiao.;Ph Gabriel Steg.;Michael Miller.;Eliot A Brinton.;Terry A Jacobson.;Jean-Claude Tardif.;Christie M Ballantyne.;R Preston Mason.;Deepak L Bhatt.
来源: Circulation. 2022年146卷5期372-379页
REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) reported a 25% relative risk reduction in major adverse cardiovascular events with use of icosapent ethyl compared with pharmaceutical grade mineral oil. The mechanisms underlying this benefit remain uncertain. We explored whether treatment allocation in REDUCE-IT might affect a series of biomarkers in pathways known to associate with atherosclerosis risk.
329. Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial.
作者: Henning Bundgaard.;Anna Axelsson Raja.;Kasper Iversen.;Nana Valeur.;Niels Tønder.;Morten Schou.;Alex Hørby Christensen.;Niels Eske Bruun.;Helle Søholm.;Muzhda Ghanizada.;Natasha A S Fry.;Elisha J Hamilton.;Søren Boesgaard.;Mathias B Møller.;Emil Wolsk.;Kasper Rossing.;Lars Køber.;Helge H Rasmussen.;Christoffer Rasmus Vissing.
来源: Circ Heart Fail. 2022年15卷7期e009120页
β3-AR (β3-adrenergic receptor) stimulation improved systolic function in a sheep model of systolic heart failure (heart failure with reduced ejection fraction [HFrEF]). Exploratory findings in patients with New York Heart Association functional class II HFrEF treated with the β3-AR-agonist mirabegron supported this observation. Here, we measured the hemodynamic response to mirabegron in patients with severe HFrEF.
330. Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial.
作者: Derek S Chew.;Yanhong Li.;Patricia A Cowper.;Kevin J Anstrom.;Jonathan P Piccini.;Jeanne E Poole.;Melanie R Daniels.;Kristi H Monahan.;Linda Davidson-Ray.;Tristram D Bahnson.;Hussein R Al-Khalidi.;Kerry L Lee.;Douglas L Packer.;Daniel B Mark.; .
来源: Circulation. 2022年146卷7期535-547页
In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In the heart failure subgroup, ablation improved both survival and quality of life. Cost-effectiveness was a prespecified CABANA secondary end point.
331. Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care.
作者: Kate Tudor.;Jenny Brooks.;Jeremy Howick.;Robin Fox.;Paul Aveyard.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷6期e007793页
The aim was to assess whether an intervention incorporating a practicable open-label n-of-1 trial would lead to greater uptake of statin than usual care and comparable uptake to a closed-label gold-standard n-of-1 trial.
332. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
作者: Javed Butler.;Amanda Stebbins.;Vojtěch Melenovský.;Nancy K Sweitzer.;Martin R Cowie.;Josef Stehlik.;Muhammad Shahzeb Khan.;Robert O Blaustein.;Justin A Ezekowitz.;Adrian F Hernandez.;Carolyn S P Lam.;Richard Nkulikiyinka.;Christopher M O'Connor.;Burkert M Pieske.;Piotr Ponikowski.;John A Spertus.;Adriaan A Voors.;Kevin J Anstrom.;Paul W Armstrong.; .
来源: Circ Heart Fail. 2022年15卷6期e009337页
We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health status outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluated whether clinical outcomes varied by baseline KCCQ score.
333. Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation.
作者: Chris Anthony.;Muhammad Imran.;Jim Pouliopoulos.;Sam Emmanuel.;James Iliff.;Zhixin Liu.;Kirsten Moffat.;Min Ru Qiu.;Catriona A McLean.;Christian Stehning.;Valentina Puntmann.;Vass Vassiliou.;Tevfik F Ismail.;Ankur Gulati.;Sanjay Prasad.;Robert M Graham.;Jane McCrohon.;Cameron Holloway.;Eugene Kotlyar.;Kavitha Muthiah.;Anne M Keogh.;Christopher S Hayward.;Peter S Macdonald.;Andrew Jabbour.
来源: Circulation. 2022年145卷25期1811-1824页
Endomyocardial biopsy (EMB) is the gold standard method for surveillance of acute cardiac allograft rejection (ACAR) despite its invasive nature. Cardiovascular magnetic resonance (CMR)-based myocardial tissue characterization allows detection of myocarditis. The feasibility of CMR-based surveillance for ACAR-induced myocarditis in the first year after heart transplantation is currently undescribed.
334. Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.
作者: Ambarish Pandey.;Matthew W Segar.;Sumitabh Singh.;Gordon R Reeves.;Christopher O'Connor.;Ileana Piña.;David Whellan.;William E Kraus.;Robert J Mentz.;Dalane W Kitzman.
来源: Circulation. 2022年146卷2期80-90页
Supervised aerobic exercise training (ET) is recommended for stable outpatients with heart failure (HF) with reduced ejection fraction (HFrEF). Frailty, a syndrome characterized by increased vulnerability and decreased physiologic reserve, is common in patients with HFrEF and associated with a higher risk of adverse outcomes. The effect modification of baseline frailty on the efficacy of aerobic ET in HFrEF is not known.
335. Sex Differences in Characteristics, Treatments, and Outcomes Among Patients Hospitalized for Non-ST-Segment-Elevation Myocardial Infarction in China: 2006 to 2015.
作者: Weihong Guo.;Xue Du.;Yan Gao.;Shuang Hu.;Yuan Lu.;Rachel P Dreyer.;Xi Li.;Erica S Spatz.;Frederick A Masoudi.;Harlan M Krumholz.;Xin Zheng.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷6期e008535页
Sex differences in clinical characteristics and in-hospital outcomes among patients with non-ST-segment-elevation myocardial infarction have been described in Western countries, but whether these differences exist in China is unknown.
336. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
作者: Ronald B Goldberg.;Trevor J Orchard.;Jill P Crandall.;Edward J Boyko.;Matthew Budoff.;Dana Dabelea.;Kishore M Gadde.;William C Knowler.;Christine G Lee.;David M Nathan.;Karol Watson.;Marinella Temprosa.; .
来源: Circulation. 2022年145卷22期1632-1641页
Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study).
337. Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial.
作者: Mohammad Alkhalil.;Michał Kuzemczak.;Robin Zhao.;Charalampos Kavvouras.;Warren J Cantor.;Christopher B Overgaard.;Shahar Lavi.;Vinoda Sharma.;Saqib Chowdhary.;Goran Stanković.;Saško Kedev.;Ivo Bernat.;Ravinay Bhindi.;Tej Sheth.;Kari Niemela.;Sanjit S Jolly.;Vladimír Džavík.
来源: Circ Cardiovasc Interv. 2022年15卷5期e011336页
It is unclear whether more effective forms of thrombus removal than current aspiration catheters would lead to improved outcomes. We sought to evaluate the prognostic role of residual thrombus burden (rTB), after manual thrombectomy, in patients undergoing primary percutaneous coronary intervention with routine manual thrombectomy in the TOTAL trial (Thrombectomy Versus PCI Alone).
338. Understanding Baseline Physical Activity in Cardiac Rehabilitation Enrollees Using Mobile Health Technologies.
作者: Jessica R Golbus.;Kashvi Gupta.;Rachel Stevens.;V Swetha Jeganathan.;Evan Luff.;Thomas Boyden.;Bhramar Mukherjee.;Predrag Klasnja.;Sachin Kheterpal.;Sarah Kohnstamm.;Brahmajee K Nallamothu.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷7期e009182页
Baseline physical activity in patients when they initiate cardiac rehabilitation is poorly understood. We used mobile health technology to understand baseline physical activity of patients initiating cardiac rehabilitation within a clinical trial to potentially inform personalized care.
339. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
作者: William A Murphy.;Nan Lin.;Amy Damask.;Gregory G Schwartz.;P Gabriel Steg.;Michael Szarek.;Poulabi Banerjee.;Sergio Fazio.;Garen Manvelian.;Robert Pordy.;Alan R Shuldiner.;Charles Paulding.
来源: Circ Genom Precis Med. 2022年15卷3期e003503页
Statin-associated muscle symptoms (SAMS) are the most frequently reported adverse events for statin therapies. Previous studies have reported an association between the p.Val174Ala missense variant in SLCO1B1 and SAMS in simvastatin-treated subjects; however, evidence for genetic predictors of SAMS in atorvastatin- or rosuvastatin-treated subjects is currently lacking.
340. Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial.
作者: Clara K Chow.;Harry Klimis.;Aravinda Thiagalingam.;Julie Redfern.;Graham S Hillis.;David Brieger.;John Atherton.;Ravinay Bhindi.;Derek P Chew.;Nicholas Collins.;Michael Andrew Fitzpatrick.;Craig Juergens.;Nadarajah Kangaharan.;Andrew Maiorana.;Michele McGrady.;Rohan Poulter.;Pratap Shetty.;Jonathon Waites.;Christian Hamilton Craig.;Peter Thompson.;Sandrine Stepien.;Amy Von Huben.;Anthony Rodgers.; .
来源: Circulation. 2022年145卷19期1443-1455页
TEXTMEDS (Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome) examined the effects of text message-delivered cardiac education and support on medication adherence after an acute coronary syndrome.
|